Search company, investor...


Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Poxel

Poxel is a biopharmaceutical company developing first-in-class drugs, with a primary focus on Type 2 diabetes. The company develops drug candidates to clinical proof-of-concept before seeking pharmaceutical industry partners. Poxel was spun out from Merck Serono. It operates independently as a lean organization with strong in-house drug development expertise. Poxel's product pipeline consists of several first-in-class Type 2 diabetes products, including Imeglimin in Phase II development. Recently, Imeglimin has also shown significant clinical benefits in Type 2 diabetes, when added to sitagliptin. The Phase II study achieved the primary and secondary endpoints. Previously, Imeglimin has shown incremental efficacy as an add-on therapy to metformin, in patients inadequately controlled by monotherapy. In addition, a direct activator of AMPK is in preclinical development for the treatment of Type 2 diabetes.

Headquarters Location

200 avenue Jean Jaurès

Lyon, 69007,


+33 437 372 012

Missing: Poxel's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Poxel's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Poxel

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Poxel is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,904 items

Poxel Patents

Poxel has filed 28 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Autosomal recessive disorders
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Human proteins, Intracellular receptors, Rare diseases, Fluoroarenes


Application Date


Grant Date



Related Topics

Transcription factors, Human proteins, Intracellular receptors, Rare diseases, Fluoroarenes



Latest Poxel News

Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

Mar 15, 2023

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023. The Company will present the positive results from the P

Poxel Frequently Asked Questions (FAQ)

  • When was Poxel founded?

    Poxel was founded in 2009.

  • Where is Poxel's headquarters?

    Poxel's headquarters is located at 200 avenue Jean Jaurès, Lyon.

  • What is Poxel's latest funding round?

    Poxel's latest funding round is IPO.

  • How much did Poxel raise?

    Poxel raised a total of $51.12M.

  • Who are the investors of Poxel?

    Investors of Poxel include Kreos Capital, Bpifrance, Omnes Capital, Andera Partners, CDC Entreprises and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.